Merkel cell carcinoma from molecular pathology to novel therapies

Abstract

Merkel cell carcinoma (MCC) is an uncommon and highly aggressive skin cancer. It de-velops mostly within chronically sun‐exposed areas of the skin. MCPyV is detected in 60–80% of MCC cases as integrated within the genome and is considered a major risk factor for MCC. Viral negative MCCs have a high mutation burden with a UV damage signature. Aberrations occur in RB1, TP53, and NOTCH genes as well as in the PI3K‐AKT‐mTOR pathway. MCC is highly immu-nogenic, but MCC cells are known to evade the host’s immune response. Despite the characteristic immunohistological profile of MCC, the diagnosis is challenging, and it should be confirmed by an experienced pathologist. Sentinel lymph node biopsy is considered the most reliable staging tool to identify subclinical nodal disease. Subclinical node metastases are present in about 30–50% of patients with primary MCC. The basis of MCC treatment is surgical excision. MCC is highly radiosen-sitive. It becomes chemoresistant within a few months. MCC is prone to recurrence. The outcomes in patients with metastatic disease are poor, with a historical 5‐year survival of 13.5%. The median progression‐free survival is 3–5 months, and the median overall survival is ten months. Currently, immunotherapy has become a standard of care first‐line therapy for advanced MCC.